Clinical Trial Update: Evaluation of FDY-5301 in Major Trauma Patients in ICU [Phase 2]

View source ↗

Summary

Phase 2 trial update for FDY-5301 in ICU-acquired weakness; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Icu-acquired Weakness

Drugs mentioned

• FDY-5301

Snippet

Sponsor: Faraday Pharmaceuticals, Inc. | Conditions: ICU Acquired Weakness | Phase 2 | Status: TERMINATED | Results posted: 2023-06-13